CoChat
Sign Up
Cited by 484Antifungal resistance and susceptibilityUrinary Tract Infections ManagementOcular Infections and Treatments

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients

Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., Mosher, A., Lee, J. Y., Dismukes, W. E., National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group·2000·Clinical Infectious Diseases
DOI 10.1086/313583
Open this paper in CoChat — free account

Abstract

Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear. This multicenter prospective surveillance study of 861 patients was undertaken to define the epidemiology, management, and outcomes of funguria. Diabetes mellitus was present in 39% of patients, urinary tract abnormalities in 37.7%, and malignancy in 22.2%; only 10.9% had no underlying illnesses. Concomitant nonfungal infections were present in 85%, 90% had received antimicrobial agents, and 83.2% had urinary tract drainage devices. Candida albicans was found in 51.8% of patients and Candida glabrata in 15.6%. Microbiological and clinical outcomes were documented for 530 (61.6%) of the 861 patients. No specific therapy for funguria was given to 155 patients, and the yeast cleared from the urine of 117 (75.5%) of them. Of the 116 patients who had a catheter removed as the only treatment, the funguria cleared in 41 (35.3%). Antifungal therapy was given to 259 patients, eradicating funguria in 130 (50.2%). The rate of eradication with fluconazole was 45.5%, and with amphotericin B bladder irrigation it was 54.4%. Only 7 patients (1.3%) had documented candidemia. The mortality rate was 19.8%, reflecting the multiple serious underlying illnesses found in these patients with funguria.

Overview

Integrity signals

Registry

Crossref · 10.1086/313583

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 2

  1. 1991, The American journal of medicine, 91, 72
  2. -1, Journal of Infectious Diseases, -1, MASTER, 10.1093/jnlids/167.5.1247 · DOI

Cited by

Sorted by citations

Items 301–400 of 484

Related

See all

Metadata

Authors
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., Mosher, A., Lee, J. Y., Dismukes, W. E., & National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group
Affiliations
  • University of Michigan (US)
  • Wayne State University (US)
  • Duke Medical Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • Boston University (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • Maimonides Medical Center (US)
  • University of Alabama (US)
Corresponding author
Kauffman, C. A.
ORCID
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2000-01-01
Volume
30
Issue
1
Pages
14-18
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1086/313583
OpenAlex
W2131468549
Cited by
483
References
17
Citations by year
2026: 10 · 2025: 11 · 2024: 10 · 2023: 16 · 2022: 22 · 2021: 25 · 2020: 12 · 2019: 25 · 2018: 20 · 2017: 22 · 2016: 18 · 2015: 25 · 2014: 19 · 2013: 19 · 2012: 15
FWCI
14.31
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01ai065296-009)
  • National Institute of Allergy and Infectious Diseases (N01AI65296)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
funguria, fungal urinary tract infection, nosocomial infections, Candida albicans, Candida glabrata, urinary catheter, antifungal therapy, fluconazole, candidemia, mortality, diabetes mellitus, underlying disease
MeSH terms
Aged, Aged, 80 and over, Antifungal Agents, Candidiasis, Catheterization, Cross Infection, Female, Hospitalization, Humans, Male, Middle Aged, Mycoses, Population Surveillance, Prospective Studies, Risk Factors, Urinary Tract Infections, Urine, Fluconazole, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review